Shanghai Jinsai Biomedical Co., Ltd. was established in Shanghai on June 6, 2000 with a registered capital of11.400 million yuan. Protein, focusing on the research and development and production of drugs for treating tumors, autoimmune diseases and senile diseases, has a high-tech platform for the research and development and production of various genetic engineering drugs with international advanced level.
The company's biomedical industrialization project began in February 2000. The main products rhTNFRII-Fc and rhPTH 1-34 entered the industrialization stage in 2009, and are undergoing phase II and III clinical trials, with the ability of mass production.